Alpha memo: resveratrol / exercise bounded update

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• Receipt 1 (2017) excerpt describes a mouse endurance study with resveratrol +/or exercise showing benefit; Receipt 2 (2014) is a human RCT where exercise but not resveratrol improved metabolic/inflammatory endpoints — the contrast is clean and well-bounded, though the memo could note the population (inactive aged men 60-72) and dose (250 mg/day, 8 weeks) more explicitly in the bounded contrast section.
• The 'Why this is surprising' framing is mild but acceptable; the surprise is bounded by the species/population/endpoint mismatch, not a paradigm shift.

Reviewer note

The memo makes one bounded research signal clear: a mouse endurance study (Receipt 1, 2017) shows resveratrol +/or exercise benefit, while a human RCT in aged men (Receipt 2, 2014) shows exercise but not resveratrol improves skeletal muscle metabolic/inflammatory markers. The alpha is correctly framed as endpoint- and setting-dependent, not a universal benefit claim. Title/source alignment is exact — both receipts test resveratrol/exercise/training on aged populations, and the contrast is explicitly bounded by species, population, and endpoint class. Limitations are honest: the pair does not isolate whether species, dose, duration, modality, or endpoint explains the split. The falsifier and evidence gap are specific and actionable (a matched human study on the same endpoint). No clinical, policy, or investment claims are made. Sources directly support the thesis with appropriate hedging language. Minor polish possible on dosage/population details but not required for acceptance.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis